SAN DIEGO – Third quarter results for fiscal year 2026 at Medtrade exhibitor Resmed revealed a revenue increase of 11% to $1.4 billion.

“Our third quarter results reflect the continued strength of our global business, driven by ongoing demand for our market-leading products and disciplined execution of our strategy,” said Mick Farrell, chairman and CEO. “Year-over-year, we delivered 11% reported revenue growth, 290 basis points of non-GAAP gross margin expansion, and 21% increase in earnings per share.

“These results highlight the momentum behind our strategy, and the continued progress we are making in shaping the future of sleep health, breathing health, and healthcare in the home,” Farrell continued via press release. As we advance through the remainder of our fiscal year 2026, we remain focused on expanding access to care globally, scaling our digital health capabilities, and delivering further strong, profitable growth.”

New CFO at Resmed
SAN DIEGO – Resmed announced last week that Brett Sandercock, chief financial officer, plans to retire effective May 4, 2026. After conducting a comprehensive search, Aaron Bloomer has been appointed as his successor.

“After 27 years with Resmed, including 20 as CFO, Brett leaves an outstanding legacy of disciplined leadership and trusted partnership,” said Mick Farrell, chairman and CEO of Resmed via press release. “Brett’s leadership has helped guide Resmed through significant growth and transformation, while keeping a clear focus on long-term value creation and our goal to improve more than 500 million lives. On behalf of the Board and the entire Resmed team, I thank Brett for his exceptional contributions and wish him all the best in his well-earned retirement.”